Cerecin, a Singapore-based biotech developer that specialises in neurotherapeutics, has announced raising $40 million in a funding round backed by South Korean investors.
The investors in Cerecin’s Series IIA funding round include lead investor SK Securities, Hana Financial Investment, Partners Investment, Arche Investment, and K&T Investment.
